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Since the first successful haematopoietic stem cell transplan-
tation (HSCT) using cord blood from a sibling in 1988 and
the establishment of the first public umbilical cord blood
bank in New York Blood Center in 1992, umbilical cord blood
banks have been instituted in many countries. Funding was
received from regular blood banks, health councils, charity
funds or commercial investments. The international medical
society is indebted to the New York Blood Center for publishing
their procedures and EuroCord for fighting a patent on cord
blood processing. Although it is unknown how many cord
blood samples are currently banked and have been trans-
planted worldwide, the figures of the international registra-
tion of World Marrow Donor Association (WHDA) show an
increase of cord blood use, in addition to other sources of
unrelated HSCT (Fig. 1).
Cord blood for HSCT is, in addition to national/regional
use, exchanged worldwide. Donor counselling, human leuco-
cyte antigen (HLA)-typing, tests for transmittable diseases
and product quality control requirements to comply with
(inter)national [AABB, Paul-Ehrlich-Institut, NetCord/
Foundation for the Accreditation of Cellular Therapy (FACT)]
standards are expensive, making storage of cord blood for
unrelated allogeneic haematopoietic transplantation currently
a loss-making activity, not particularly attractive for private
enterprise. In the last years, hopes have been fueled that other
stem cells in cord blood may be used for future repair of
metabolic or degenerative diseases. Autologous or personal
cord blood banking appeals to individual initiatives and
private funding; money is desperately needed by allogeneic
cord blood banks, and it would be much better if it could






















become available to the latter. In spite of the fact that the
probability for the use of autologous cord blood is extremely
low (estimates range from 1 : 1400 to 1 : 200 000), almost
500 000 autologous cord blood samples (two to three times
the number of allogeneic cord blood units) are stored in the
USA [1]. In some countries such as India, only private cord
blood banks are operating. We aimed to make an inventory
of how professional standards of current cord blood banks
respond to autologous public cord blood banking. We sent out
questionnaires to NetCord-associated banks and national




. Is/are there cord blood bank(s) in your country
in which samples of allogeneic cord blood are stored in
non-for-profit institutions? Are they part of a national or
international network? Which authority is responsible for
these cord blood banks? Do the banks offer opportunity to store
allogeneic related cord blood (directed) and/or autologous




. Do you agree that some conditions treatable with
allogeneic cord blood are already present in the stem cells of
the infant, and that therefore such conditions should be treated
with allogeneic rather than autologous cord blood? Do you
nevertheless feel that the storage of samples of autologous cord
blood should be encouraged? If so:
• Should the samples be stored in the not for profit bank
where allogeneic blood is stored?
• If you think they should be stored in separate banks, who
should be responsible for these banks and how should
quality control be assured?
• Do commercial banks to store autologous blood samples
already exist in your country?
• Which authority is responsible for these banks?
• How is the quality control of such blood banks assured?
• Are these banks also involved in storing allogeneic




. Which do you consider appropriate indications for
storing directed (related and/or autologous) cord blood samples?
Unfortunately, only 10 responses were received, a dis-
appointing number. However, an interesting international
scenario is nevertheless revealed.
In all responding countries, allogeneic (anonymous) cord
blood banks are operated by public non-for-profit institutions
and the majority are or are in the process of operating in
national and international networks, including accreditation.
All allogeneic cord blood banks offer, in principle, facilities
for the storage of related donations. Generally, the public
cord blood banks offer storage of related cord blood samples
on request of a transplant physician or a physician who takes
care of an affected family member (which often implies that
the costs are reimbursed). None of the public cord blood
banks currently store autologous cord blood. 
In all the participating countries, except the Netherlands
and Italy, one or many private autologous cord blood banks
are operating. In Italy, private cord blood banking is prohibited,
but agents of the international private banks do operate in
the Netherlands and Italy with regard to the organization of
the collection and exportation of autologous units. In most
countries, there is a clear separation between public and
private banks with respect to scientific cooperation, quality
control, exchange and the responsible authorities. Exceptional
situations exist in Turkey and Iran. In Turkey, regulated
by law and supervised by the Minister of Health, private
autologous cord blood banks are obliged to offer 25% of their
stock for allogeneic use, which implies certification and
Good Manufacturing Practice (GMP) inspections by health
authorities. One such private bank has been certified and five
are under evaluation. As there are five public cord blood
banks, this may result in an almost equal number of private
and public banks complying with the same quality criteria.
In Iran, a private autologous cord blood has been running for
several years, operated by a scientific institute. The expertise,
management and supervisory board of this private cord
blood bank will be used as a model for the non-for-profit
anonymous allogeneic/dedicated cord blood bank, which
aims to join NetCord. In other countries, autologous cord
blood banks received local licences and accreditation and
none is supervised by an external responsible authority.
None of the responding authors favours encouraging storage
of autologous cord blood for haematopoietic reconstitution.
The prospect of storing autologous stem cells from other than
haematopoietic origin is considered immature and informa-
tion about what and how to store them is yet not available.
In some countries such as Germany, autologous banking
is not recommended by the Health Council advisory board
(Bundesärztekammer), although nevertheless private
autologous cord blood banks do operate. Other European
countries refer to the Council of Europe Act 2004/23 that
does not preclude autologous cord blood banking, but its
requirements discourage personal cord blood banking,
because the lack of prospect for future usage must be clearly
mentioned to the ‘investors’. In some countries such as the
Netherlands, the decision to combine autologous with
allogeneic cord blood banking is still pending. The public
support and the assumption of profit from autologous cord
blood banking allowing funding of allogeneic cord blood
banking is currently explored. Others point to the delicate
conflict of interest that can arise combining private and
public interest, and warn that if equal quality levels are applied,
autologous cord blood banking will be less profitable.
All of the responding authors favour encouraging directed
cord blood donations in particular for siblings with a
hereditary disease, for example, haemoglobinopathies. Many
suggest that a list of indications for directed cord blood






















countries require a physician’s signature as a guarantee for
reimbursement.
In conclusion, currently there is, in most of the responding
countries, a clear separation between autologous and alloge-
neic cord blood banks with respect to funding, quality (control),
certification and responsible authorities. All allogeneic banks
offer storage of related cord blood, albeit that reimbursement
within the healthcare system is often a prerequisite. There is
agreement that if scientific research supports autologous
cord blood storage, this should be accessible for all patients
and incorporated in current public allogeneic banks.
There is much interesting information in the answers from
the participants, which cannot be mentioned in this Editorial.
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Cord blood stem cells may be donated to a bank for a poten-
tial match to any patient who has a disease treatable with
allogeneic haematopoietic stem cell therapy. This is a proven
and increasingly common practice and has important social
value. Whether the allogeneic bank is managed by public or
private operators is not critical, provided the activity is run
in accordance with the international NetCord/FACT cord
blood standards, compliance is documented by NetCord/
FACT accreditation and the service of allogeneic cord blood
procurement is provided for a reasonable fee.
In Belgium, there are five cord blood banks storing samples
of allogeneic cord blood: the Liège Cord Blood Bank at the
University of Liège in Liège, the Louvain Cord Blood Bank at
the Catholic University of Louvain in Brussels, the Brussels
Cord Blood Bank at the Free University of Brussels in Brussels,
the Leuven Cord Blood Bank at the Catholic University of
Leuven in Leuven, and the Gent Cord Blood Bank at the
University of Gent in Gent. They are all part of public university
hospitals. The first three banks form a network of cord blood
banks with a common inventory under the hub of the Liège
Cord Blood Bank; they are affiliated both with the Belgian
registry of marrow donors (the Marrow Donor Program –
Belgium) and the NetCord international network of cord
blood banks. The Leuven cord blood bank is also affiliated
with NetCord, while the Gent Cord Blood Bank is only
participating in the Marrow Donor Program – Belgium. The
cord blood banks must obtain certification from the Ministry
of Public Health after expert advice from the Upper Health
Council on a yearly basis, with a full inspection once every
3 years. The Liège Cord Blood Bank has obtained NetCord/
FACT accreditation in 2005, while the Louvain, Brussels and
Leuven Cord Blood Banks are in the process of sending their
checklist to FACT in the first part of 2008 in preparation for
the NetCord/FACT audit. The banks all offer the opportunity
to store directed allogeneic related cord blood when a biological
sibling has a disease treatable by allogeneic HSCT. None of





Some commercial banks are operating in Belgium, offering
families the opportunity to store autologous cord blood
samples. They receive cord blood units from Belgium as well
as from some foreign countries. As they are not undertaking
allogeneic cord blood banking, they are not submitted to the
same process of certification by the Ministry of Health. After
expert advice from the Consultative Bioethics Council and
the Upper Health Council, a Royal Decree was published in
2002, forbidding the collection and storage of autologous cord






















potential (genetic disease in the family ... ) for its therapeutic
use. The decree was challenged in court by a commercial bank,
suspended in 2003 and cancelled in 2005. Since then, there
is no law regulating cord blood banking activities in Belgium.
The 2004/23/CE European directive published on 31 March
2004 has not yet been translated into Belgian law; several
proposals are under discussion in parliament. There is no specific
quality control on these banks; none of them has obtained or
even applied for NetCord/FACT or equivalent accreditation.
If some day autologous cord blood banking is promoted by
society, it should be carried out in public cord blood banks
that offer certified guarantees of: absence of conflict of interest;
appropriate consent process based on complete, unbiased
and balanced information; equal access to all families; and
quality assurance system documented by NetCord/FACT
accreditation and national certification. However, there is




Cord blood cells should be collected and preserved in families
where a biological sibling has a disease treatable by allogeneic
HSCT. This is a medical practice of proven benefit. These
diseases should include all those for which allogeneic stem
cell transplantation is indicated as currently recognized by
international expert organizations, such as the European
Blood and Marrow Transplant Group, and possibly all
malignant, genetic and severe autoimmune diseases. The
stored cord blood unit could then provide the necessary stem
cells for allogeneic and/or autologous transplantation with
or without genetic manipulation.
There is no appropriate indication for autologous cord
blood banking when there is no such disease in the family or
a high risk thereof. There are two broad purposes for which
collection of autologous cord blood units is advertised, that
is, autologous HSCT and tissue regeneration.
1. Autologous HSCT. HSCT is a proven therapy for
selected patients with life-threatening malignancies, genetic
disorders and autoimmune diseases. Both autologous and
allogeneic HSCT can be performed, mostly depending on the
disease and age of the patient.
• For malignant disorders, allogeneic HSCT is generally
preferable to autologous HSCT, because the donor’s
immune cells can eliminate the patient’s residual
malignant cells through the graft-versus-leukaemia
effect. There is no such effect after autologous HSCT,
rendering it less effective to treat leukaemias and other
haematopoietic malignancies.
• Studies have demonstrated the presence of preleukaemic
and leukaemic cells in the cord blood of children who
later develop leukaemia. Because these preleukaemic
cells could cause a leukaemia relapse, the use of
autologous cord blood for the treatment of childhood
leukaemia would be contraindicated.
• Because HSCs in cord blood carry the same genetic
defects as the patients’, autologous cord blood trans-
plantation cannot be used to treat any genetic diseases
amenable to allogeneic HSCT, such as haemoglobin-
opathies, immune deficiencies or storage disorders.
• If autologous HSCT is the preferred option for a patient,
physicians would favour the collection and trans-
plantation of peripheral blood stem cells (PBSC) over
that of cord blood stem cells. Indeed, hematopoietic
reconstitution is much faster with PBSC, reducing the
duration of hospitalization, the risk of infection and
the overall cost of treatment. Cord blood would thus be
an option only for the 5–10% of patients who are poor
mobilizers. 
• Many cord blood units would not be usable, because
they contain too few nucleated cells. The Liège Cord
Blood Bank discards two-thirds of collected units because
of low cell count. Among the remaining top third of








 nucleated cells/kg as a threshold
for autologous transplantation, 99% are suitable for
children of 20 kg of body weight, but this figure drops
to 39% when body weight reaches 60 kg. 
• In addition, the cost of collecting autologous cord blood
in all neonates and using it in very few of them far
exceeds that of collecting and transplanting PBSC when
a patient needs them. Belgium counts 10 000 000
inhabitants and approximately 70 000 births per year.













150 per year). The
costs of banking cord blood units from all Belgian
















3000). The risk of
needing an autologous HSCT between 0 and 20 years of
age is less than 0·01% (i.e. 100/year for Belgium). Hence,
if all autologous HSCT were done with cord blood, the













5000 for PBSC. In a more realistic context where
cord blood is used only when PBSCs are not collectable
and the number of nucleated cells is adequate for trans-
plantation, the cost would even be 20–40 times this
figure. The number per year would be < 2–5/10 million
inhabitants.
2. Tissue regeneration. Stem cells could be used in the future
for tissue repair for degenerative or ischemic diseases of the
heart (myocardial infarction), liver, muscle, brain (Alzheimer,
Parkinson), endocrine system (diabetes), and other organs.
Research investigates the potential of embryonic stem cells,
fetal stem cells (including cord blood) and adult stem cells for
that purpose.
• Basic research has demonstrated the existence of
pluripotent stem cells in cord blood that can differentiate






















tissues. However, these cells are present in very low
numbers and cannot be retrieved from all cord blood
units, in particular from those that have been cryopre-
served. It is unknown whether current freezing methods
used by cord blood bank would preserve them during
long-term storage.
• Experiments using cord blood for tissue regeneration in
animals are performed with allogeneic or xenogeneic,
not with autologous, cord blood cells. Allogeneic cord
blood could become a valuable source of stem cells for
this purpose.
• There is no scientific evidence that cord blood contains
unique stem cell populations that are not present in
adult tissues such as the bone marrow, from which
much larger numbers of them can potentially be collected.
Furthermore, the cost of collecting autologous cord









10 500] and using it in few of them




10 500 000) that of collecting
and transplanting marrow stem cells when a patient
needs them.
• Clinical protocols of tissue regeneration use essentially
autologous bone marrow or mobilized peripheral blood
cells, with some preliminary but promising success. No
clinical protocol has shown a benefit of autologous
cord blood.
• Most of the potential diseases (myocardial infarction,
Alzheimer’s or Parkinson’s diseases, ... ) for which
regenerative medicine could be an indication occur in
patients older than 50 years. What the status and
treatment of these diseases will be in 50 years is quite
impossible to predict and there is a major risk that all
cord blood units collected today will just become
obsolete, because other forms of prevention and therapy
will have become available. In addition, more stringent
quality standards would likely replace current ones and
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Six allogeneic unrelated cord blood banks are located in
Germany that store cord blood in non-profit institutions. The
largest cord blood bank with 13 796 (June 2008) stored unrelated
cord blood units is the José Carreras Cord Blood Bank in
Düsseldorf, the next largest is located in Gauting with 2356
cord blood units (www.netcord.org; June 2008); Mannheim
with 1652 cord blood units (www.netcord.org), and banks with
smaller inventory are found in Dresden, Freiburg and Erlangen.
The cord blood inventory of the banks in Duesseldorf,
Mannheim and Gauting are listed with the international
NetCord organization. Due to very strict regulations of the
German pharmaceutical production law and the European
guidelines, all cellular products must be produced under
appropriate GMP conditions in class 100 (EU class A) in an
environment in class 1000 (EU class B). Each unrelated cord
bank in Germany is required to have legal permission from
the local authorities to produce and cryopreserve cord blood
products and, in addition, a licence from the Paul-Ehrlich-
Institute (Federal Agency for Sera and Vaccines).
The banks that store unrelated cord blood in Germany also
provide the opportunity to store directed cord blood in case
there is a family indication and upon request of the physician.
Autologous cord blood samples are not stored in these banks,
based on the statement found in the national guidelines of the
official organ of the German Federal Chamber of Physicians
(Bundesärztekammer) ‘to date there are no medical indications




We agree that some conditions treatable with allogeneic cord
blood are already present in the stem cells of the infant. The
experience of the Duesseldorf Cord Blood Bank shows that
three children who donated cord blood developed acute
lymphoblastic leukaemia and therefore the cord blood could
not be used for transplantation.
At present, there seems to be no need to store cord blood
for autologous use. The data available worldwide show that
among 2 000 000 stored autologous cord blood units, only 12
were used in a clinical situation [2], in which an unrelated cord
blood could also have been used or in a situation in which the
treatment/chemotherapy alone was sufficient to cure the child.
In a paper from the American Academy of Paediatrics, it was
discussed that the likelihood of children to need their own cord
blood stem cell is from 1 in 1000 to less than 1 in 200 000 [3].
As stated in the position statement on cord blood for
autologous use by the NetCord foundation as of January
2008 [4], the following points should be mandatory for
consideration:
If autologous cord blood is stored, the process of collection,






















blood cells should fulfil international standards, such as
developed by NetCord/FACT. These standards can be
ensured by NetCord/FACT accreditation of the cord blood
banks. In addition, the information given to the parents or
guardian of an infant must be complete, unbiased and
balanced. The informed consent process shall include the
purpose of stem cell collection, the possible benefits and
risks, and the likelihood that the cells may be used for that
particular purpose. Donors shall not be misled about the
potential for cells to be used to treat future disease in that
donor or to regenerate tissue. Conflicts of interest must
be disclosed. The American Academy of Pediatrics
made it very clear that the private storage of cord blood
as ‘biological insurance’ should be discouraged [3]. The
statements of the World Marrow Donor Association (WMDA)
[5] and the European Group of Ethics in Science and New
Technologies [6] and many other organizations are of the
same opinion.
In Germany, six to eight commercial cord blood banks exist
to store autologous cord blood samples. Legal permission
from local authorities to produce and cryopreserve autologous
cord blood products serves as the basis for quality control.
As no or very few autologous units are released for trans-
plantation, data on the ultimate quality control of engraftment
and survival are lacking. In addition, the numbers of nucleated
cells in the cord blood units stored in these banks are much
lower than in allogeneic unrelated units.
 
New variations on donating Cord Blood 
 
In addition to the public and private donation of cord blood
a new type of cord blood donation is now possible in a private
company which is, however, legally and morally questionable.
This alternative appears to bridge the gap between donating
for public use and storing for private use: cord blood can be
stored privately when a fee is paid and, if required, it can be
released anonymously to a patient. At first glance this varia-
tion might look like a sensible solution to the contradiction
between “Donating versus Private Storage” since it combines
both possibilities. This practice is, however, not compatible
with the German standards for a non-related blood stem cell
donation. These standards specify that the consent form for
donating must include a passage stating that the “expectant
mother transfers the collected cord blood to the cord blood
bank and waives any claims on it” (7). Moreover, this option
is not morally acceptable, since it presents the parents with a
dilemma to decide once again. They have already spent a
considerable sum of money for the storage of their child’s
cord blood because they truly believe these cells have great
potential use for their child in the future. Now they are forced
to decide whether they should give this blood to another
person, since, for example, the patient (a child with leukemia)
might otherwise die without it. If they decide to release the
cord blood to the patient, the money the parents spent is
refunded. This decision, difficult enough as it is concerning
the fate of another person, possibly even to decide over life
or death, is also dependent on economic factors. Is it really
fair to put the parents through such a decision making process?
This is not the same situation a bone marrow donor faces who
is able to decline at any time prior to donation. By contrast,
a bone marrow donation is not without risks to the donor,
further the actual bone marrow donation is not performed at
the time of registration and the donor can also become sick
after registering with the bone marrow registry. The cord





An appropriate indication for storing directed related cord
blood within a family is given, if a sibling already presents
an indication (malignant and non-malignant disease) as
documented by a physician. However, even in this situation,
the parents must be well-informed that statistically there is
only a 25% chance that the cord blood will be HLA-matched
and therefore the best stem cell source. If the sibling cord
blood shows HLA-mismatches, an unrelated cord unit might
be preferred for several indications.
Moreover, the storage of autologous cord blood should not
be recommended for families, which are at risk for a genetic
disease (e.g. severe combined immunodeficiency disease),
which could be treated with a cord blood allogeneic stem cell
preparation.
During the last 10 years, the public relation activities of the
majority of companies storing cord blood for autologous use
switched from the treatment of haematological diseases (as
clinical data was not sufficiently convincing in contrast to
allogeneic cord blood transplantation) to the possible future
use in regenerative medicine.
Although there are unique cell populations in cord blood
(30–40% of cord blood samples) with high proliferative
potential and differentiation potential, several of the popu-
lations cannot be recovered from cryopreserved samples or
only in very small numbers.
Due to these difficulties to generate rare cells from cryop-
reserved material, therapeutic application of cord blood cells
will probably have to rely on the establishment of fresh cord
blood cell banks, with the cells generated from fresh cord
blood.
In addition, parents who store cord blood for autologous
use must be informed that there are also alternative cell
sources, such as autologous bone marrow, which could be
used at any time during life.
Although cord blood is a very unique cell source and many
papers have been published during the last years on tissue
regenerating populations in cord blood, some of the data,
unfortunately, are not very consistent and should be recon-
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Recently, we establish the non-for-profit cord blood bank
beside our private Royan Cord Blood Bank.
Unfortunately, not yet, but it is our plan to be a part of a
national or an international network as soon as possible.
The Royan Research Institute is responsible for the non-
for-profit cord blood bank. 
We have planned to develop our non-for-profit bank for
both purposes, for treatment of some blood diseases and for




We do agree that such a bank should be non-for-profit,
because all of us have the goal to rescue patients, whether
they are rich or not. But in some cases when there is a specific
disease in the familial history, the probability of the use of
autologous cord blood stem cells is high. Maybe in this situa-
tion such a family will prefer to use a private cord blood bank.
Usually, a scientific group should be responsible for private
cord blood banks and the Ministry of Health (public health
and/or specific disease office) should have control of the
activity of such banks.
In our country (Iran), we have a private cord blood bank
that has been active for 2 years and stores about 3000 units.
The Royan Stem Cell Technology is responsible for our
private cord blood bank that is linked to the Royan Institute.
The Scientific Board who are academic staff and all our
physicians, technologists follow the JACIE & NetCord/FACT
standards. In addition, this centre has been controlled by the
public health and specific disease office of Iranian Ministry
of Health.





In some families with a high incidence of a specific disease

















Italian cord blood banks storing cord blood units for allogeneic
transplantation are non-for-profit institutions belonging
to the public National Health System. In 1996, seven banks
coordinated by the Milano Cord Blood Bank voluntarily
formed the GRACE (Gruppo per la Raccolta e l’Amplificazione
delle Cellule Emopoietiche – Group for the Collection and
Expansion of Hemopoietic Cells) network [1]. During 1996–
2006, GRACE developed an IT protocol for data sharing into
a unique inventory managed by the central hub in Milan,
which performed preliminary and extended cord blood unit
searches on behalf of the member banks. In 2007, the cord
blood searching registry was transferred to the Italian Bone
Marrow Donor Registry in Genua, which currently manages
the national cord blood registry and performs cord blood unit
searches. The data from the Italian cord blood banks are also
exported to NetCord and to BMDW [2].
Currently, cord blood banking falls under blood transfusion
law no. 219/2005 and derived norms.
A significant reorganization of the Italian cord blood
banking network, aimed at including all active banks, was
started in 2007 through the combined efforts of the National
Transplant Centre and the National Blood Centre in Rome. A
national survey on 2007 data was recently completed to






















total of 19 banks with a global inventory of about 22 000
cord blood units, whose 84% HLA typed, responded to the
survey. A detailed report of the 2007 survey will be published
soon. At 31 December 2007, 634 cord blood units were
released for allogeneic transplantation.
Responsibility for the cord blood banks belongs to the 20
Italian regions, which have the authority to accredit the
banks based on a national set of standards. The process of
regional accreditation is currently under development. The
banks in Milan and Pavia have also been accredited by the
FACT.
Directed cord blood units are stored at no charge to the
family for consolidated indications of family related haemo-
poietic transplantation. In agreement with the recommenda-
tions of several expert groups and scientific societies,
autologous cord blood storage is not offered by the Italian
cord blood banks, with the exception of the cord blood bank
in Mantua. As a result of the current cord blood banking
ordinance, which prohibits private cord blood banking and
the request of a monetary fee to the donor, families opting
for autologous cord blood storage export the units to foreign
banks.
The transplantation procedures performed with cord stem
cells complying with the national and international guidelines
and standards (GITMO – Italian Cooperative Group for Bone




Several reports in the literature document the presence of
‘defective’ stem cells in the prenatal phase of subjects later
diagnosed with conditions requiring bone marrow replacement.
Such cases must be treated with an allogeneic rather than an
autologous haemopoietic stem cell source in order to prevent
recurrences and to exploit the transplant versus cancer effect.
For this scientific motivation and for the high possibility of





 90%) in case of hypothetical therapeutic need, the autologous
storage should not be encouraged.
Although in principle it is largely understandable why a
significant number of families are attracted by the option of
autologous cord blood storage through aggressive com-
munication media campaigns, we share the views of experts
who do not recommend this practice, for the following reasons:
(i) there are no proven therapeutic protocols; (ii) costs are
substantial; (iii) post-storage cell traceability and quality
after several decades is not known; (iv) autologous storage
may reduce cord blood availability for allogeneic transplants
of proven effectiveness; (v) probability of use is exceedingly
low; (vi) biological materials including blood and cord blood
should be considered as a common good and not as a com-
modity. In addition, it should be explained to families that
haemopoietic progenitors potentially amenable to the same
innovative tissue reparative treatments that will hopefully be
developed in the future for cord blood are cultured and nurtured
in optimal conditions in the bone marrow throughout our





Through the combined effort of several experts of the GITMO,
the Associazione Italiana Ematologia Oncologia Pediatrica
(Italian Society of Pediatric Hematology Oncology) and the
European Blood and Marrow Transplant Group [3], Italian
cord blood banks may refer to a recently defined detailed list
of approved conditions for directed cord blood storage,
which belong to the following main categories: leukaemia
and lymphoma, myelodisplastic and myeloproliferative
syndromes, plasma cell disorders, severe aplastic anaemia
and bone marrow failure syndromes, haemoglobinopathies,
histiocytosis, congenital immune disorders, inherited
metabolic diseases, osteogenesis imperfecta and a few others.
In addition to approved indications, physicians requesting
directed cord blood storage must document the clinical
appropriateness of the planned transplantation procedure.
Directed cord blood storage for families at high risk of gene-
tically transmissible conditions treatable with haemopoietic
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E. D. Calderón Garcidueñas
Question 1
In Mexico, there are three public cord blood banks: CordMX
Centro Nacional de Transfusión Sanguínea (CNTS) health
ministry, La Raza Cord Blood Bank IMSS at Mexico City and
Hospital Universitario de Nuevo León Cord Blood Bank at
Monterrey Nuevo León.
Only CordMX Cord Blood Bank is part of a national and
international network. CordMX is an associated member of
NetCord (http://www.netcord.org/) since 2006. The health
ministry is the authority responsible for these cord blood
banks, through the CNTS (https://www.cnts.salud.gob.mx/)
and the Comisión Federal para la Protección contra el Riesgo
Sanitario (http://www.cofepris.gob.mx/).
The CordMX offers the opportunity to store allogeneic related
cord blood (directed) only in case a patient is a candidate for
transplantation and the mother is already pregnant. This
service must be required by the transplant centre. CordMX do not
offer the opportunity to store autologous cord blood samples.
Question 2
Yes, CordMX agrees that some conditions treatable with
allogeneic cord blood are already present in the stem cells of
the infant and that therefore such conditions should be
treated with allogeneic rather than autologous cord blood.
In reference to the storage of samples of autologous cord blood,
we think that it can be allowed but it should not be encouraged.
The principal problem with autologous cord blood banks
in Mexico is that in most of the private cord blood banks the
units are not tested in accordance with international standards,
thus 100% of the recollected units are stored, but half of these
units are not fit for transplantation.
If, for some reason, somebody needs to store autologous
cord blood, it should be stored in a non-for-profit bank.
In Mexico, there are about 16 commercial banks to store
autologous blood samples. As there is no national law that
regulates these banks, they work only with a sanitary licence
emitted by the Ministry of Health (Comisión Federal para la
Protección contra el Riesgo Sanitario). These commercial
banks do not apply the NetCord international standards.
Question 3
CordMX considers that there are no indications for autologous
storage. For related storage, only in the case of patients with
oncology and a disease not requiring bone marrow trans-
plantation, and their mother has a healthy pregnancy.
E. D. Calderón Garcidueñas
Subdirectora de Investigación
CordMX BSCU
Centro Nacional de la Transfusión Sanguínea




J. M. van Beckhoven, H. J. C. de Wit, W. E. Fibbe et al.
Question 1
In the Netherlands, anonymous allogeneic cord blood units
are collected, tested and stored in a national cord blood bank
under the responsible authority of Sanquin, the Dutch blood
supply institute, a not-for-profit organization supervised by
the Ministry of Health. The Sanquin cord blood bank has a
standing agreement with two other Dutch foundations,
Europdonor and EuroCord. Europdonor is the national
unrelated stem cell donor bank and hub centre, responsible
for making the ca. 3600 Dutch cord blood transplants available
for search in BMDW and holding contacts with the transplant
centres for selection and delivery arrangements. EuroCord
Nederland is represented in NetCord/FACT and participates
in international platforms for qualifications and the medical
use of cord blood transplantation.
The Dutch cord blood bank also acts as intermediary for
the collection and storage of cord blood from relatives
intended for allogeneic related transplantation. Guidelines
for indications are periodically provided by the Dutch societies
of Paediatrics and Haematology and the cord blood bank only
accepts these directed cord bloods on request of the treating
physician of the potential recipient. The costs associated
with related cord blood storage are reimbursed by the health
insurance of the patient or by the search budget of the transplant
centre. For autologous cord blood storage, there are no pro-
cedures and no facilities in the country, although every hospital
running an accredited stem cell laboratory can collect and store
directed and autologous cord blood units for its own use.
Question 2
We do agree that some conditions treatable with allogeneic
cord blood might be present in the infant’s stem cells. The
Dutch cord blood bank EuroCord Nederland excludes
cord blood when certain hereditary diseases are present in
the family, or in the case of leukaemia in first- and second-
line relatives. The cord blood from relatives is only used for
directed donation on request of the transplant centre.
There are no public or private banks for autologous cord
blood in the Netherlands, but some Belgian private banks do
operate in our country. The issue of the storage of autologous
cord blood, lacking the prospect of a specific treatment
intention in the public bank, is under debate in our country.
If scientific evidence will emerge that autologous cord
blood may serve as a tool for the repair of haematopoietic or
degenerative diseases for which the current treatment is
already covered by health insurance, accessible to all civilians,
it is obvious that the not-for-profit cord blood bank is the
designated organization for autologous cord blood collection
and storage, fulfilling all quality regulations. For indications
lacking a scientific basis, there is poor ground for using public
money for the storage of autologous cord blood. However,
for civilians who express, despite state of art information as
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required by the CoE 2004/23, a strong desire to have access
to stored autologous cord blood at their own expense, the
decision to combine private and public banking has not yet
come to conclusions. Many obstacles have to be overcome,
among others the policy of the Dutch blood supply to offer
expertise and facilities for autologous use of blood products
solely on medical indications.
If, on the other hand, private cord blood banks will be estab-
lished, we assume that quality requirements will be in accordance
with the law on safety and qualification of human cells, con-
trolled by the National Health Inspection. Permission from this
authority is also required for the import of autologous cord blood
from Belgium (or other countries). As far as we are informed,
autologous cord blood has not yet been imported or used.
Question 3
Currently, as mentioned above, the Dutch cord blood bank
accepts directed cord blood intended for allogeneic use on the
request of a physician of a transplant centre. Indications
include haemato-oncological diseases and hereditary diseases
that can also be treated by allogeneic related or unrelated
stem cells from adult donors. If after HLA-typing and
additional investigations for the absence of the hereditary
disease the donor is declared unsuitable for directed use, the
product can only be used for research, because EuroCord
Nederland standards do not allow these donations for unre-
lated use. For autologous cord blood storage, indications do not
exist and if such indications emerge, they are best integrated
in the not-for-profit cord blood bank.
Close monitoring of scientific progress about repair by auto-
logous cord blood stem cells is a joint responsibility of several
experts in order not to miss opportunities for future patients.
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In Russia, three non-for-profit cord blood banks exist in
Moscow, Samara and Kazan. At present, they are not part of
national or international network. The Moscow and Samara
cord blood banks are in the process to join EuroCord/NetCord.
Regional governments are responsible for these cord blood
banks. So far, the banks have only collected cells while no
transplantations have yet been performed.
Question 2
Six commercial banks to store autologous cord blood samples
already exist in Russia (Hemabank, Moscow; Cryocenter,
Moscow; Flora-Med, Moscow; Pokrovsky stem cells bank;
Saint-Petersburg; Hemabank, Saint-Petersburg; and Trans-
Technologies’s, Saint-Petersburg). 
All the banks are licenced by the federal health control service.
There is no authority responsible for these banks. Sometimes
stem cells are insured by a private insurance company.
Hemabank (Moscow) has one example of successful (4
years ago) allogeneic cord stem cells transplantation from a
younger brother to treat neuroblastoma.
Question 3
The indications are quite common. Family anamnesis of
malignant and hereditary diseases may be an indication to
store directed (related and/or autologous) cord blood samples.
E. B. Zhiburt
Head Transfusionist 
Pirogov Russian National Medical Surgical Center




T. Bart, for the Swisscord Commission
Question 1
In Switzerland, there are two non-for-profit cord blood
banks, one in Basel and one in Geneva, in which cord blood
units are stored for allogeneic transplantation.
These two public banks are operated under the responsi-
bility of the departments of haematology together with the
departments of laboratory medicine and gynaecology of
the university hospitals of the respective cities and under
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the surveillance of the national regulatory authority (Swiss
Institute for Therapeutic Products/Swissmedic). The respective
cord blood banks are in charge of processing and storage of
cord blood products.
The Swiss national blood stem cell donor registry (Swiss
Foundation Blood Stem Cells) is – as in the case of adult blood
stem cells – in charge of all activities related to national and
international exchange of cord blood products destined for
transplantation. Its specialist commission Swisscord, con-
sisting of representatives of the registry as well as specialists
in haematology, gynaecology, laboratory medicine and
blood transfusion, decides upon policies and other medical-
related activities in public cord blood banking and cord blood
transplantation.
As regards directed cord blood banking, the banks offer the
possibility of directed banking in case there is a sibling of the
newborn with a disease that can be treated by allogeneic HSCT.
Question 2
A well-matched allogeneic cord blood unit is usually preferable
to an autologous cord blood unit not only because of the
potential presence of malignant or premalignant stem cells,
but also because of the potential of a graft versus leukaemia
effect. Therefore, cord blood banks should provide cord blood
units with a large choice of HLA phenotypes and haplotypes and
autologous cord blood storage should not be promoted actively.
The potential conflict of interest between commercial
and non-for-profit banks should be seriously taken into
consideration upon the decision to store autologous cord blood
units in the same cord blood bank as allogeneic cord blood.
A commercial organization operating in this field should
be responsible for its own activity and products. It has to be
assured that an equivalent quality control as it is applied
upon public banks for allogeneic products should be in force.
There are at least three or four commercial firms active in
the storage of autologous blood samples to our knowledge.
Swissmedic is responsible for these banks.
The quality control of such blood banks is assured by the
regulatory authority (Swissmedic), which begins to run
inspections, to our knowledge.
These banks are only involved in storing autologous cord
blood units, to our knowledge.
Question 3
The indications for storing directed cord blood samples should
be the same as those for allogeneic stem cell transplantations.
T. Bart
Chief Operating Officer







Cord blood is a source of stem cells since 1995 in Turkey.
However, the indications are limited: it is used mainly for
paediatric patients who do not have an HLA-identical sibling
and need an allogeneic stem cell transplantation urgently [1].
For patients who can afford to wait until the matched sibling
is grown up to the age of donation, paediatric transplant
teams prefer to use bone marrow for transplantation and keep
the cord blood as a backup. During the last 2 years, unrelated
cord blood transplants have become a frequent treatment for
both paediatric and adult patients. For patients who lack
a family donor and carry rare HLA haplotypes, unrelated
cord blood is a life-saver. As elsewhere, the percentage of
cord blood among unrelated paediatric transplants is also
approaching 50% in our country [2].
For these reasons, in Turkey, cord blood collection and
storage was initiated in accredited academic institutions
where autologous stem cell, either bone marrow or stem cell,
collection and storage are standardized procedures. There are
only five active cord blood banks that collect cord blood for
allogeneic purposes. With the exception of one, these are all
located in academic institutions and are non-for-profit
organizations. These banks do not belong to a national or an
international network yet. One of the academic allogeneic
cord blood banks gave start to the first unrelated cord blood
banking activity in Turkey in 2004. TR1CB is recognized by
BMDW and is listed on the website.
There is a national regulation prepared and run under the
directory of the Ministry of Health on cord blood banking.
This regulation defines the criteria for national accreditation
and audit of private banks who plan to collect and store
autologous cord blood. It requires a minimum of 25%
allogeneic cord blood storage at private banks. A national
advisory board of experts appointed by the Ministry of
Health for 1-year term fulfils the decision-making require-
ments defined by the regulation. Since the institution of this
regulation in 2005, only one bank has been able to get a
certificate from the Ministry of Health. There are at least five
cord blood banks who have applied for approval and are
under evaluation.
In Turkey where the birth rate is still higher than in many
countries, autologous private cord blood banking boomed in
early 2000s. However, both the Ministry of Health and
medical organizations led by mainly haematologists and
obstetricians prevented illegal banking activities that purely
aimed at financial gains and did not meet medical or
scientific requirements. The Turkish Society of Hematology
has addressed the public by many means including advertise-
ments in daily newspapers to prevent private cord blood
banks from misleading people by inaccurate information on
the need of autologous storage. 
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Question 2
As stated recently by the American Society of Blood and
Bone Marrow Transplantation, the chances for a need for
autologous cord blood in general are so low that it can be
neglected [3]. Furthermore, autologous adult stem cells can
be obtained from various tissues. The current medical practice
does not involve the use of such autologous cells for the
treatment of aplastic anaemia or leukaemia for which
allogeneic stem cell transplantation offers a long-term cure.
Numerous reports on the very early detection of leukaemic
cells in the prenatal life many months preceding the diagnosis
of paediatric postnatal leukaemia hinders the use of autologous
cord blood. Moreover, graft versus leukaemia is a proven
benefit of allogeneic transplantation and is much less evident
with autologous cells [3].
Acquired aplastic anaemia may be the only condition in
which storage of unaffected autologous cord blood can be a
life-saver. It is also important to mention that the probability
of aplastic anaemia is approximately 1 in 10 000 and can be
cured by means other than autologous cord blood, that is,
HLA-matched stem cells from family members or unrelated
donors [3].
Cord blood is a useful source of stem cells. The major
limitation is that the number of stem cells is sufficient for
only small sized recipients and that there is a delay in
engraftment. Another weakness is the lack of the capacity of
a strong immune response. Thus, the question that we are
trying to answer is not only a qualitative comparison between
allogeneic cells vs. autologous cells, from which for almost
all situations allogeneic cells win, but also involves the
quantitative sufficiency of cord blood as well. If cord blood
is stored in facilities accessible to all those in need in a non-
profit fashion, the need for autologous storage will diminish.
This will spare a waste of cord blood resulting from many
years of storage without a necessity for use in the owner
while it could have been used for a subject who has a disease
that could be treatable with these cells. It is also important
and should not be forgotten that once the owner is above a
certain weight, usually 20–30 kg, depending on the number
of stem cells present in his cord blood [4], it will not be
sufficient for a stem cell transplantation and the benefits of
cord blood stem cells for long-term treatment of degenerative
diseases of the elderly is still an ongoing debate.
We recommend that cord blood should be stored in allogeneic/
altruistic facilities that are non-profit organizations and are
open to access.
In an ideal world in which all cord bloods in the depository
are available, depending on the need defined by HLA
frequencies, cell content, blood group, etc., there will be no
need for separate banks for autologous cord blood banking.
The management of altruistic cord blood banks must be
performed locally. However, accreditation by national and
international authorities must be encouraged. All banks must
abide to standards defined by international organizations.
Thus, such cells can be transportable without any concerns
about their quality or ethics.
Currently, there is only one private cord blood bank,
which is a joint organization of a university hospital with a
private sector and has received the cord blood certificate
from the Ministry of Health. Unfortunately, the private
autologous cord blood banks that were active before the
institution of the national regulation in 2005 continued
storage despite the lack of certification by the national
authority. Some have transported cord blood to other
countries in the past, although it is against the law. Some
of these banks have submitted their application and
approval is expected to follow.
The Ministry of Health is responsible for these banks.
The regulation of 2005 enforces these banks to comply
with the GMP requirements. The advisory board and the GMP
inspectors of the ministry ensure that the banks fulfil these
criteria. Control of quality assurance and management is
maintained by continuous audits.
The regulation mandates that at least 25% of the cord
blood stored in the bank is allogeneic. Usually the academic
allogeneic cord blood banks are sufficient for this purpose
and there is hardly a need for storage in private banks. Even
if the families accept donation for altruistic purposes, stem
cell quantification and HLA-typing costs are limiting factors
in such conditions.
Question 3
From the mid-1990s, when allogeneic cord blood trans-
plantation became available in Turkey, thalassaemia is the
number one indication that is followed by acute lymphoblastic
leukaemia in second remission or first remission with poor
prognostic features and acute myelogenous leukaemia. As
prenatal diagnosis of thalassaemia is widely applicable in our
country, prenatal or postnatal HLA typing has guided us in
the decision making of cord blood storage for directed
purposes. A complete HLA-match based on molecular HLA-
A, -B, -C and -DRB1 typing is required for the storage of allo-
geneic cord blood for either benign or malignant disorders.
For patients who have an HLA-identical sibling cord blood
timing of transplantation and use of cord blood must be made
by the paediatric transplant team. Due to limitations in
storage capacity, one haplotype-matched allogeneic cord
blood can be discarded unless the stem cell content is very
high. If altruistic banking is available, cord blood from siblings
proven not to carry the disease can be stored regardless of the
HLA-match degree. For directed cord blood collection and
storage, paediatricians must publish and update the list of
diseases treatable with stem cell transplantation. Such lists
are currently available [3]. Treatment of adult disorders
including diabetes, Alzheimer’s and Parkinson’s disease is
certainly not among the list of indications.
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In some situations when a patient is in need of a trans-
plantation and no family donor is found, assisted in vitro
fertilization and selection of embryos with HLA-match have
led to successful pregnancies and transplantation. However,
such an approach involves many ethical concerns and conflicts.
In situations in which diseases treatable with stem cell
transplantation are frequent within the family or are expected
to occur more frequently than in the general population,
autologous cord blood can be stored depending on the decision
of the relevant physicians and paediatricians including
geneticists. However, currently such situations are extremely
rare and are expected to be higher in families with con-
sanguineous marriages.
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C. Navarrete & F. Regan
Question 1
Currently, there are two non-for-profit cord blood banks in
the UK storing samples for clinical use, the National Health
Service Cord Blood Bank (NHS CBB) (formerly the London
Cord Blood Bank) [1] and the Northern Ireland (NI) Cord
Blood Bank. The units from these two cord blood banks are
registered with the British Bone Marrow Registry (BBMR) for
national searches and through the BBMR with the BMDW
Registry for international searches. In addition, all the units
from the NHS CBB, which is NetCord/FACT accredited, are
also listed with NetCord.
The National Health Service Blood and Transplant authority
is responsible for the NHS CBB and the Northern Ireland
Blood Service is the authority responsible for the NI units.
The NHS CBB also runs a national programme to collect
related (directed) cord blood units for patients with a variety of
conditions including malignant and non-malignant disorders,
such as acute and chronic leukaemia, haemoglobinopathies
and immunodeficiencies. However, the majority of the units
went to patients with non-malignancies [2]. The request for
these collections is initiated by the treating physician and
requires the consent of the obstetrician responsible for the
delivery of the baby. The NHS CBB is not involved in the
collection of autologous units.
Question 2
There is evidence that preleukaemic mutations can be
present in the cord blood of babies who develop leukaemia
years later [3]. We are aware therefore that many transplant
physicians would not wish to use autologous cord blood, but
would choose an allogeneic source of stem cells in preference.
Autologous cord blood could be stored in case a sibling should
ever develop a disease requiring a cord blood transplant and
in the hope that the cord is a suitable match. However, the
chances of the stored cord blood being used are low (estimates
vary between 1 in 1400 to 1 in 20 000) [4]. Many transplant
physicians would prefer, if possible, to wait until the cord
donor child has grown a little, then procure bone marrow as
a source of a larger dose of stem cells. Autologous cord blood
could be stored for the future as a source of multipotent
mesenchymal stem cells for potential use in regenerative
medicine (e.g. to treat cardiac or neurological disease).
There is some evidence of progress in using these in animal
experiments and some early trials are underway in humans,
but it is too early to draw conclusions about clinical effec-
tiveness of these cells. Furthermore, it is not yet clear which
is the optimal source of these cells and at present these cells
be obtained from several sources including bone marrow,
cord blood or cord matrix (Wharton’s jelly) [5]. The viability
of the haematopoietic or mesenchymal stem cells stored for
decades, until the appearance of diseases that might require
their use, is not currently known. On balance, we conclude
that there is not at present sufficient evidence to justify or
indeed promote the storage of autologous cord blood.
If autologous cord blood is collected, it could in principle
be stored in a non-for-profit bank alongside allogeneic cord
blood donations. Indeed, one advantage might be that pri-
vately funded autologous donations could help to financially
support the allogeneic cord bank. However, to ensure the
microbiological safety of the allogeneic units stored, either
the autologous units would have to be subject to the same
microbiological testing and the same degree of donor
questioning for risk factors for infectious diseases (to minimize
the risk of ‘window period’ infections), in order to minimize
the risk of transmission during storage, or the autologous
units would need to be reliably segregated from the allogeneic
units. Apart from the issue of storage in the same bank, if the
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same collection staff were used to approach donors for
allogeneic and autologous units, there would be a potential
conflict of interest in terms of which form of donation the
collectors would encourage the donors to choose. On balance,
separate storage of autologous and allogeneic cord blood
donations would be preferable.
Cord blood banks for storing autologous donations should
be subject to the same national and international regulations
and accreditation schemes that are applicable to the cord
blood banks storing allogeneic donations. These include:
NetCord/FACT International Standards for Cord Blood
Collection, Processing, Testing, Banking, Selection and Release
[6], EU Directive 2004/23/EC on setting standards for quality
and safety in the donation, procurement, processing, preser-
vation, storage and distribution of human tissues and cells
[7], Human Tissue Act [8] and the Food and Drug Adminis-
tration Eligibility Determination for Donors of Human Cells,
Tissues and Cellular and Tissue-Based Products [9]. Inspections
with a view to accreditation aim to determine that appropriate
quality assurance systems are in place.
In the UK, several commercial banks store autologous cord
blood (http://www.parentsguidecordblood.com/content/
usa/banklists/summary.shtml#uk). They need to be MHRA
accredited and need to comply with the Human Tissue Act
and EU Directive and can voluntarily apply for NetCord/
FACT accreditation.
Question 3
Same as answer to Question 1 for directed donations. For
autologous donations, we cannot comment on appropriate
indications – see answer to Question 2.
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